Regenxbio (RGNX) Current Deferred Revenue (2014 - 2025)

Regenxbio's Current Deferred Revenue history runs 11 years deep, the most recent figure standing at $10.5 million for Q4 2025.

• In Q4 2025, Current Deferred Revenue rose 8988.7% year-over-year to $10.5 million; the TTM figure through Dec 2025 stood at $10.5 million (up 8988.7% YoY), while the FY2025 annual figure was $10.5 million, up 8988.7% from the prior year.
• Current Deferred Revenue was $10.5 million for Q4 2025 at Regenxbio, down from $13.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $39.9 million in Q1 2025 to a low of $13000.0 in Q1 2024.
• Historically, Current Deferred Revenue has averaged $6.9 million across 5 years, with a median of $3.3 million in 2021.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue tumbled 99.01% in 2024, then surged 306707.69% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $3.3 million in 2021, then sank by 45.12% to $1.8 million in 2022, then plunged by 91.91% to $148000.0 in 2023, then declined by 22.3% to $115000.0 in 2024, then soared by 8988.7% to $10.5 million in 2025.
• The last three Current Deferred Revenue figures came in at $10.5 million (Q4 2025), $13.2 million (Q3 2025), and $37.8 million (Q2 2025), per Business Quant data.